Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A multicenter cohort study of 1.8 million clinic encounters reveals that while clinicians view intraocular pressure as a continuous risk factor, the historical 22 mm Hg cutoff remains a significant psychological trigger for escalating glauc
The Diabetes Endothelial Keratoplasty Study (DEKS) confirms that donor diabetes status has no clinically significant impact on 1-year graft success rates or endothelial cell loss after Descemet membrane endothelial keratoplasty (DMEK), faci
Two Phase 3 trials show that NT-501 encapsulated cell therapy significantly reduces ellipsoid zone area loss in Macular Telangiectasia Type 2. While functional outcomes were inconsistent, the treatment demonstrated a robust neuroprotective
Three cases of pentosan polysulfate maculopathy occurred after subcutaneous administration for arthritis at much lower cumulative doses than oral use, highlighting retinal toxicity risk and need for early detection.
This post hoc analysis of the PULSAR trial reveals that aflibercept 8 mg provides noninferior visual outcomes and comparable anatomic regression to standard 2 mg dosing in PCV patients, while allowing for significantly extended treatment in
A Cochrane review of seven RCTs (494 participants) finds low- to very low-certainty evidence that select medical therapies — notably recombinant human nerve growth factor — may improve corneal re-epithelialization in neurotrophic keratopath
A Cochrane review of 22 cohort studies (6,082 patients) found bilateral disease, disc haemorrhage, female sex, and active treatment have the most consistent associations with visual-field progression in open-angle glaucoma, but overall evid
This case series reviews clinical features, genetic variants, visual outcomes, and psychosocial impact in 28 patients with USH1C-associated Usher syndrome, highlighting slow retinal degeneration and significant social burden.
In children after primary congenital glaucoma surgery with poor spectacle response, rigid gas‑permeable contact lenses produced greater improvements in worse‑eye visual acuity, contrast sensitivity, and near stereoacuity over 12 months comp
A prospective PEDIG cohort found modest long-term vision after lensectomy for pediatric traumatic cataract, low 5-year glaucoma prevalence, and high 5-year surgery rates for visual axis opacification in pseudophakic eyes, especially without
A randomized noninferiority trial found that a device-free manual marking-assisted capsulorhexis (MMAC) produced capsulorhexis diameters and centration comparable to digital guidance (DGAC), supporting a low-cost, widely applicable techniqu
Contemporary foundation models match experts on text-only ophthalmology exam questions but underperform on image-based items; targeted multimodal training and prospective validation are needed before clinical deployment.
A Gut 2025 study identifies microbially produced indole-3-propionic acid (IPA) as a protective metabolite linking restored intestinal tryptophan handling to prevention of diabetic retinopathy in mice and associates low serum IPA with retino
The FDA has rejected Sydnexis’s low-dose atropine eye drop SYD-101 for controlling childhood myopia progression despite promising trial results, highlighting challenges in demonstrating long-term efficacy and clinical significance in
A biodegradable PLGA microsphere–thermo‑responsive hydrogel delivering aflibercept was well tolerated after single intravitreal injection in 23 rhesus macaques with preserved retinal structure and function up to 24 months.
A prospective phase IV open‑label Chinese study found cenegermin achieved corneal healing in 84.6% of stage 2/3 neurotrophic keratopathy patients at 8 weeks, with durable effects through 56 weeks and an acceptable safety profile.
This cohort study tracks diabetic retinopathy incidence over 24 years in type 2 diabetes patients, highlighting the impact of glycemic control and hypertension on disease progression.
GLP-1 receptor agonists used in diabetes show a twofold increased risk of neovascular AMD, a modest risk elevation for diabetic retinopathy, and a small but significant increased risk for nonarteritic anterior ischemic optic neuropathy, war
A large retrospective cohort study reveals that GLP-1 receptor agonists significantly reduce the risk of developing nonexudative age-related macular degeneration in obese individuals without diabetes, with no effect on progression to exudat
Recent clinical trials report encouraging tumor shrinkage with KRAS G12D inhibitor VS-7375, significant progression-free survival benefit in soft tissue sarcoma with ozekibart, and a novel gene therapy acquisition targeting wet AMD.
Open language-specific specialty feeds and department pages.